# eMed

**Source:** https://geo.sig.ai/brands/emed  
**Vertical:** Digital Health  
**Subcategory:** Metabolic Health  
**Tier:** Challenger  
**Website:** emed.com  
**Last Updated:** 2026-04-14

## Summary

Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.

## Company Overview

eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.

The platform's capitated pricing model shifts financial risk from employers to eMed — charging a fixed fee per member regardless of how many GLP-1 prescriptions are written — which makes total cost predictable for HR and benefits teams wrestling with runaway drug spend. GLP-1 medications (Ozempic, Wegovy) have become the most requested workplace health benefit in the US, and their list prices create budget pressure that employers urgently need managed.

eMed combines clinical oversight (prescribers, pharmacists, registered dietitians) with behavioral coaching and medication management to improve outcomes and reduce GLP-1 discontinuation, which runs 50-70% in typical commercial populations. The company's approach is to treat GLP-1 therapy as a managed clinical program rather than a pharmacy benefit, driving the adherence rates it claims as a differentiator.

## Frequently Asked Questions

### What does eMed do?
GLP-1 and metabolic health benefits platform for employers — capitated pricing model shifts drug cost risk away from HR, with 91%+ claimed medication adherence.

### How much has eMed raised?
$200M Series A at $2B+ valuation in March 2026, led by AON Consulting.

### Who leads eMed?
Linda Yaccarino, former CEO of Twitter/X, serves as CEO. Tom Brady is among the backers.

### Why is GLP-1 benefits management a growth market?
GLP-1 medications are the most requested workplace benefit in the US. Their high list prices create budget pressure employers urgently need managed through specialized clinical programs.

### What is eMed and what metabolic health services does it offer?
eMed is a metabolic health company offering weight management programs using GLP-1 medications (such as semaglutide and tirzepatide) combined with personalized coaching, nutrition support, and medical supervision delivered via telehealth.

### How does eMed provide access to GLP-1 medications?
eMed provides access to GLP-1 medications through licensed physicians who evaluate patients via telehealth visits, write prescriptions where clinically appropriate, and coordinate with pharmacies for medication fulfillment.

### What does eMed's weight management program include beyond medication?
eMed's program includes registered dietitian coaching, behavior change support, metabolic health tracking, and ongoing medical supervision to support sustainable weight loss and metabolic improvement alongside medication.

### Does eMed accept insurance for its metabolic health programs?
eMed works with select insurance plans and employers for coverage, and also offers self-pay options. Coverage for GLP-1 medications varies significantly by payer and plan.

## Tags

b2c, healthtech, mobile-first

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*